ArticleCell genomics2024
Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome.
Article in Cell genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Immune-Enriched Versus Matrix-Remodeling Microenvironments in Psammoma Body-Rich and Psammoma Body-Poor WHO Grade I Meningiomas: An Exploratory Transcriptomic Study.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026Article
- Optic nerve sheath meningioma exhibits neural niche-associated transcriptomic features and rare copy number variation-linked evolution.Brain pathology (Zurich, Switzerland) · 2026Article
- Current evidence on the cell of origin of meningiomas disputes the arachnoid cap cell dogma.Acta neurochirurgica · 2026Review
- Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines.bioRxiv : the preprint server for biology · 2026Article
- Beyond Histology: A Unified Transcriptomic Atlas Defines Lung Cancer Biologic States and Subtypes.bioRxiv : the preprint server for biology · 2026Article
- A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.Nature genetics · 2026Article
- Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology.Neuro-oncology · 2026Article
- Trends in meningioma-related mortality among U.S. adults: A CDC WONDER analysis from 2000 to 2023.Surgical neurology international · 2026Article
- Novel insights into hypoxia-driven transcriptomic and epigenetic landscapes in grade 3 meningioma.Journal of translational medicine · 2025Article
- Subgroup of meningiomas involving FOS and FOSB gene fusions.Nature communications · 2025Article
- Integrative transcriptomics and network analysis reveals core genes driving meningioma pathogenesis and clinical outcomes.Scientific reports · 2025Article
- Determining the Biological Features of Aggressive Meningioma Growth with Transcriptomic Profiling.Cancers · 2025Article
- Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.Neuro-oncology · 2025Article
- In Silico Identification of circPIM1/miR-16-5p/miR-195-5p/PIM1 Feed-Forward Loop in Recurrent Grade 2 Meningioma.International journal of molecular sciences · 2025Article
- Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology.bioRxiv : the preprint server for biology · 2025Article
- Total whole-arm chromosome losses predict malignancy in human cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- RNA polymerase II at histone genes predicts outcome in human cancer.Science (New York, N.Y.) · 2025Article
- Identification of a Novel Oxidative Stress-Based Molecular Classification and Treatment Vulnerabilities in WHO Grade 2/3 Meningiomas.Oncology research · 2025Article
- Seq-ing answers: exploring meningioma biology utilizing bulk RNA-seq-based reference landscapes.Frontiers in oncology · 2025Review
- RNA Polymerase II hypertranscription at histone genes in cancer FFPE samples.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Meningiomas, although mostly benign, can be recurrent and fatal. World Health Organization (WHO) grading of the tumor does not always identify high-risk meningioma, and better characterizations of their aggressive biology are needed. To approach this problem, we combined 13 bulk RNA sequencing (RNA-seq) datasets to create a dimension-reduced reference landscape of 1,298 meningiomas. The clinical and genomic metadata effectively correlated with landscape regions, which led to the identification of meningioma subtypes with specific biological signatures. The time to recurrence also correlated with the map location. Further, we developed an algorithm that maps new patients onto this landscape, where the nearest neighbors predict outcome. This study highlights the utility of combining bulk transcriptomic datasets to visualize the complexity of tumor populations. Further, we provide an interactive tool for understanding the disease and predicting patient outcomes. This resource is accessible via the online tool Oncoscape, where the scientific community can explore the meningioma landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.